aMoon leads round to expand product portfolio and advance
commercial efforts for MOBILion's SLIM technology for
biotherapeutics characterization and novel biomarker
discovery
CHADDS FORD, Pennsylvania, Aug. 17, 2020 /PRNewswire/ -- MOBILion
Systems, Inc., a pioneer in fast, efficient, high- resolution
instrumentation for biomarker discovery, diagnostics and
therapeutic development, today announced a $35 million Series
B funding round. The oversubscribed round was led by aMoon, with
the remaining funds contributed by existing investors, including
Agilent Technologies (NYSE: A), IP Group, Hostplus and Cultivation
Capital.
MOBILion intends to use the funds to build the commercial team
supporting the launch of the company's first product based on the
patented ion mobility separations technology, called Structures for
Lossless Ion Manipulation (SLIM). MOBILion's SLIM
technology rapidly and efficiently separates, identifies and
analyzes even the most challenging, clinically significant
molecules that other instruments fail to detect, enabling earlier
disease detection, improved diagnostic accuracy and treatment
options, along with reduced healthcare costs. It delivers
unprecedented high-resolution, high-throughput analysis for the
pharmaceutical industry and clinical researchers, significantly
enhancing the characterization of protein-based biotherapeutics and
accelerating biomarker discovery. Additionally, the
Company plans to expand the development of its product
portfolio for pharma QC and diagnostic applications.
In a very short time the company achieved all of its Series A
milestones and earned a strong market response for its first
product, which launched to select beta users in July 2020, and was offered to customers via
sample analysis collaborations in MOBILion's applications
laboratory. The product will be fully launched in
North America in 2021.
Pharmaceutical customers are using SLIM to address deficiencies in
characterization of biologic therapeutics, specifically for glycan
analysis, peptide mapping, intact, and subunit protein analysis,
which are critical quality assays that remain challenging or
impossible to adequately achieve with existing
liquid-chromatography mass spectrometry workflows.
MOBILion's patented product is being employed for glycan
characterization of the spike protein that decorates the surface of
COVID-19 (SARSCoV2) and its interaction with the host cell receptor
angiotensin converting enzyme 2 (ACE2). The glycan analysis of
COVID-19 could add to the understanding of how the virus binds to
its target and provide researchers with valuable insights that are
essential for the development of an effective treatment.
"We are very excited to have aMoon join our existing community
of investors, who collectively share our vision to advance
healthcare and improve how we predict, diagnose and treat disease
by revealing molecules that other instruments leave unseen," said
MOBILion's CEO Melissa Sherman,
Ph.D. "We are fueled by the positive feedback related to our beta
launch and validation of our first product's capabilities as
demonstrated through published accomplishments of our early
adopters and industry recognition and awards. This round of
financing will augment our sales and marketing efforts and
accelerate the development of second-generation
products."
"We share a common vision with MOBILion to develop and
commercialize breakthrough technologies that offer unparalleled
resolution and speed," said Todd Sone, Partner at aMoon who joins
MOBILion's board. "MOBILion is our latest in a series of
investments in the 'omics' space, and we look forward to supporting
Melissa and her outstanding team as they advance large molecule
development and novel biomarker discovery."
MOBILion is commercializing SLIM technology-based products that
are integrated with several industry-leading mass spectrometry
platforms to dramatically advance the capabilities of liquid
chromatography-mass spectrometry (LC-MS) workflows to efficiently
reveal previously undetectable molecules. The SLIM technology can
be integrated with LC-MS workflows to provide more robust
analytical information, and for some applications, can even replace
liquid chromatography separations to provide superior resolution,
speed, ease of use and greater instrument uptime. MOBILion's first
product is integrated with Agilent's high resolution QToF mass
spectrometer. MOBILion is also developing an easier to use,
operator-simplified stand-alone SLIM product that does not require
integration with a mass spectrometer for translation to
pharmaceutical quality control and diagnostic
laboratories.
About MOBILion Systems, Inc.
MOBILion Systems is enabling advancements in disease diagnosis and
treatment by commercializing instruments that improve drug, and
biomarker discovery. Enhancing the study of the complement to
genomics provides a better understanding of disease and drug target
mechanisms and paves the way for earlier disease detection, more
accurate diagnostics, improved treatment options for individual
patients and reduced healthcare costs.
MOBILion's instruments provide unprecedented speed and
resolution, allowing rapid detection of clinically relevant
molecules such as proteins, peptides, metabolites, glycans, lipids,
etc., to accelerate biologic drug development and biomarker
discovery. MOBILion's instruments process population-scale samples
in days vs. years and detect molecules never before seen with
existing instrumentation, providing researchers and clinicians with
the ability to better predict, diagnose and treat disease.
The company is headquartered in Chadds
Ford, Pennsylvania within the Philadelphia biopharmaceutical and medical
innovation corridor. More information can be found at
mobilionsystems.com
About aMoon
aMoon is a global healthtech and life sciences VC fund based in
Israel. The fund aims to
accelerate cure for life-threatening diseases and reduce major
cost-drivers in healthcare, by leveraging the growing convergence
of healthcare and technology. Learn more by visiting the
website, www.amoon.fund.
CONTACTS
MOBILion Systems
Katie Spruance, 610-291-2649
katie.spruance@mobilionsystems.com
McDAY – Public Relations
Alison Guzzio, 484-459-3243
alisong@mc-day.com
1515 Market St #1200
Philadelphia, PA 19102Media
contact for aMoon
Julie Steigerwald
GK for aMoon, +972 54 8360371
julie@gkpr.com